menu
    • menu

    Company profile for Alteogen

    NEW Drugs in Dev: 9
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2008, Alteogen is a leading bio company whose portfolio includes next-generation Biobetter, with improved efficacy in comparison with existing biologics, biosimilars that demonstrate “comparability” to the existing biologics, and proprietary biologics. Alteogen focus on the three cutting edge areas of the industry – long-acting biobetters, proprietary antibody-drug conjugate, and antibody biosimilars with comp...
    Founded in 2008, Alteogen is a leading bio company whose portfolio includes next-generation Biobetter, with improved efficacy in comparison with existing biologics, biosimilars that demonstrate “comparability” to the existing biologics, and proprietary biologics. Alteogen focus on the three cutting edge areas of the industry – long-acting biobetters, proprietary antibody-drug conjugate, and antibody biosimilars with complexity. Currently, Alteogen has developed NexP™ Fusion Technology, a next-generation long-acting biobetter technology on its own, developed NexMab™ ADC Technology, an Antibody-Drug Conjugate technology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alteogenkorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    62, Yuseong-daero 1628beon-gil, Yuseong-gu, Daejeon, 34054
    Telephone
    Telephone
    +82-42-384-8780
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.alteogen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alteogen
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    MAGHREB Pharma Expo

    MAGHREB Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    MAGHREB Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alteogen Licenses Hybrozyme To Biogen For Subcutaneous Biologics
    Alteogen Licenses Hybrozyme To Biogen For Subcutaneous Biologics

    25 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alteogen-enters-into-a-license-agreement-with-biogen-for-development-and-commercialization-of-hybrozyme-based-subcutaneous-biologics-302724668.html

    PR NEWSWIRE
    25 Mar 2026
    Share Share
    Alteogen Secures Exclusive License For Subcutaneous Dostarlimab
    Alteogen Secures Exclusive License For Subcutaneous Dostarlimab

    21 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alteogen-announces-exclusive-license-agreement-with-tesaro-a-subsidiary-of-gsk-for-the-development-of-a-subcutaneous-formulation-of-dostarlimab-enabled-by-hybrozyme-technology-302665173.html

    PR NEWSWIRE
    21 Jan 2026
    Share Share
    Merck Gets EU Approval For First Subcutaneous Cancer Treatment,
    Merck Gets EU Approval For First Subcutaneous Cancer Treatment,

    21 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/merck-receives-eu-nod-for-first-subcutaneous-formulation-promising-faster-cancer-treatment-18291

    INDPHARMAPOST
    21 Nov 2025
    Share Share
    Alteogen Gets EU Approval for Aflibercept Biosimilar Eyluxvi
    Alteogen Gets EU Approval for Aflibercept Biosimilar Eyluxvi

    17 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alteogen-receives-european-commission-approval-for-aflibercept-biosimilar-eyluxvi-alt-l9-302558913.html

    PR NEWSWIRE
    17 Sep 2025
    Share Share
    CHMP Backs Alteogen’s Aflibercept Biosimilar EYLUXVI (ALT-L9)
    CHMP Backs Alteogen’s Aflibercept Biosimilar EYLUXVI (ALT-L9)

    28 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alteogen-receives-positive-chmp-opinion-for-aflibercept-biosimilar-eyluxvi-alt-l9-302514688.html

    PR NEWSWIRE
    28 Jul 2025
    Share Share
    AstraZeneca signs Alteogen deal worth up to $1.35B
    AstraZeneca signs Alteogen deal worth up to $1.35B

    19 Mar 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astrazeneca-signs-135b-alteogen-deal-subcutaneous-cancer-drugs-despite-merck-halozyme-patent

    FIERCE PHARMA
    19 Mar 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search